REMS
Contraindicated in:
Use Cautiously in:
CV: edema, hypertension, hypotension, tachycardia
Derm: rash
Endo: hyperglycemia
F and E: hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia
GI: anorexia, constipation, diarrhea, nausea, vomiting, abdominal pain, GI BLEEDING
GU: renal impairment
Hemat: leukocytosis, leukopenia, thrombocytopenia, anemia, pure red cell aplasia
Neuro: anxiety, confusion, dizziness, headache, insomnia, paresthesia, sedation, tremor, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
Misc: fever, infection (including activation of latent viral infections such as Polyomavirus-associated nephropathy or Hepatitis B/C), acute inflammatory syndrome, MALIGNANCY
Drug-drug:
Mycophenolate Mofetil
Mycophenolic Acid
Mycophenolate Mofetil
Renal Impairment
Mycophenolic Acid
Absorption: Following oral and IV administration, mycophenolate mofetil is rapidly hydrolyzed to mycophenolic acid (MPA), the active metabolite. Absorption of enteric-coated mycophenolic acid (Myfortic) is delayed compared with mycophenolate mofetil (CellCept).
Distribution: Cross the placenta and enter breast milk.
Protein Binding: MPA: 97%.
Half-Life: MPA: 8–18 hr.
(MPA plasma concentrations)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| mycophenolate mofetil-PO | rapid | 0.25–1.25 hr | N/A |
| mycophenolic acid | rapid | 1.5–2.75 hr | N/A |
NDC Code